Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Meropenem

FDA-approved product (injectable, injection), marketed as Meropenem, Meropenem And Sodium Chloride In Duplex Container, Merrem Iv.

Registered studies
50+
Lab records
263
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Meropenem
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial meningitis
  • Bacteriemia
  • Infection
  • Infectious meningitis
  • Meningitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH02

Repurposing investigation

Meropenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA96.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli99.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 16 of 17 lab records
  • E. coli: measured active in 38 of 38 lab records
  • K. pneumoniae: measured active in 172 of 208 lab records
Open Meropenem in ChEMBL Registered studies below
Show the latest 150 of 263 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Meropenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

    NCT04238390 · start 2022-01

    Registered record
    Registry ID
    NCT04238390
    Conditions
    Bacteremia Caused by Gram-Negative Bacteria
    Interventions
    Ceftolozane-Tazobactam; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2022-01
    Completion
    2024-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia Caused by Gram-Negative Bacteria
    InterventionCeftolozane-Tazobactam; Meropenem
    PhasePhase 3
    Registry statusWithdrawn

  • Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

    NCT04882085 · start 2021-08-26

    Registered record
    Registry ID
    NCT04882085
    Conditions
    Urinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia; Bacteremia; Intra-abdominal Infection
    Interventions
    Zavicefta, Ceftazidime-Avibactam; Best Available Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-08-26
    Completion
    2023-08-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia +2 more
    InterventionZavicefta, Ceftazidime-Avibactam; Best Available Treatment
    PhasePhase 4
    Registry statusCompleted

  • Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

    NCT04785924 · start 2021-06-07

    Registered record
    Registry ID
    NCT04785924
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
    Interventions
    Imipenem+Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-06-07
    Completion
    2023-01-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
    InterventionImipenem+Relebactam
    PhasePhase 4
    Registry statusWithdrawn

  • Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.

    NCT04671589 · start 2021-06

    Registered record
    Registry ID
    NCT04671589
    Conditions
    Drug Toxicity
    Interventions
    Meropenem Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06
    Completion
    2022-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Toxicity
    InterventionMeropenem Injection
    PhasePhase 4
    Registry statusUnknown

  • Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

    NCT03840148 · start 2019-08-07

    Registered record
    Registry ID
    NCT03840148
    Conditions
    Urinary Tract Infections; Acute Pyelonephritis
    Interventions
    Cefepime/VNRX-5133 (taniborbactam); Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-08-07
    Completion
    2021-12-14
    Enrolment
    661

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Acute Pyelonephritis
    InterventionCefepime/VNRX-5133 (taniborbactam); Meropenem
    PhasePhase 3
    Registry statusCompleted

  • Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

    NCT03582007 · start 2018-10-22

    Registered record
    Registry ID
    NCT03582007
    Conditions
    Pneumonia
    Interventions
    Murepavadin; One anti-pseudomonal antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-10-22
    Completion
    2019-07-17
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionMurepavadin; One anti-pseudomonal antibiotic
    PhasePhase 3
    Registry statusTerminated

  • Non-operative Treatment of Acute Non-perforated Appendicitis

    NCT04030741 · start 2018-09-01

    Registered record
    Registry ID
    NCT04030741
    Conditions
    Acute Appendicitis
    Interventions
    Meronem and flagyl; Appendectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2020-12-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis
    InterventionMeronem and flagyl; Appendectomy
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases

    NCT03643497 · start 2018-07-01

    Registered record
    Registry ID
    NCT03643497
    Conditions
    Children；Infection
    Interventions
    anti-infective drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-07-01
    Completion
    2021-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildren；Infection
    Interventionanti-infective drugs
    PhaseNot recorded
    Registry statusUnknown

  • Bolus Versus Continuous Infusion of Meropenem

    NCT03452839 · start 2018-06-05

    Registered record
    Registry ID
    NCT03452839
    Conditions
    Antibiotic Resistant Infection; Critical Illness
    Interventions
    Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-06-05
    Completion
    2022-12-01
    Enrolment
    607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Resistant Infection; Critical Illness
    InterventionMeropenem
    PhasePhase 4
    Registry statusCompleted

  • A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

    NCT03329092 · start 2018-04-05

    Registered record
    Registry ID
    NCT03329092
    Conditions
    Complicated Intra-abdominal Infection; Hosptial Acquired Pneumonia; Ventilator Associated Pneumonia
    Interventions
    ATM-AVI; MTZ; MER; COL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-04-05
    Completion
    2023-02-23
    Enrolment
    422

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-abdominal Infection; Hosptial Acquired Pneumonia; Ventilator Associated Pneumonia
    InterventionATM-AVI; MTZ; MER; COL
    PhasePhase 3
    Registry statusCompleted

  • Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units

    NCT03440216 · start 2018-03-15

    Registered record
    Registry ID
    NCT03440216
    Conditions
    Pharmacokinetics; Anti-Bacterial Agents; Infection, Bacterial; Infections, Respiratory; Infection; Drug Monitoring
    Interventions
    blood sampling; Tissue sampling (lung); Collection of fluid samples
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-03-15
    Completion
    2022-12-15
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics; Anti-Bacterial Agents; Infection, Bacterial; Infections, Respiratory +2 more
    Interventionblood sampling; Tissue sampling (lung); Collection of fluid samples
    PhaseNot applicable
    Registry statusUnknown

  • Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

    NCT05896930 · start 2017-11-09

    Registered record
    Registry ID
    NCT05896930
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Meropenem 6g IV over 6 hours; Ertapenem 1g IM; Meropenem 3g IV; Ertapenem 1g IV; Amoxicillin/CA twice daily; Rifampicin 35 mg/kg; Meropenem 6g IV over 60 minutes; Rifafour e-275; Meropenem 4g IV; Amoxicillin/CA once daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-11-09
    Completion
    2021-01-04
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionMeropenem 6g IV over 6 hours; Ertapenem 1g IM; Meropenem 3g IV; Ertapenem 1g IV +6 more
    PhasePhase 2
    Registry statusCompleted

  • Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

    NCT03032380 · start 2017-10-24

    Registered record
    Registry ID
    NCT03032380
    Conditions
    Healthcare-associated Pneumonia (HCAP); Hospital Acquired Pneumonia (HAP); Ventilator Associated Pneumonia (VAP)
    Interventions
    Cefiderocol; Meropenem; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-24
    Completion
    2019-04-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthcare-associated Pneumonia (HCAP); Hospital Acquired Pneumonia (HAP); Ventilator Associated Pneumonia (VAP)
    InterventionCefiderocol; Meropenem; Linezolid
    PhasePhase 3
    Registry statusCompleted

  • Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB

    NCT03174184 · start 2017-08-23

    Registered record
    Registry ID
    NCT03174184
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Rifampin; MEROPENEM 2 grams TID; MEROPENEM 1 gram TID; MEROPENEM 3 grams QD; Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet; Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-08-23
    Completion
    2022-05-13
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionRifampin; MEROPENEM 2 grams TID; MEROPENEM 1 gram TID; MEROPENEM 3 grams QD +2 more
    PhasePhase 2
    Registry statusCompleted

  • Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

    NCT02894684 · start 2017-01

    Registered record
    Registry ID
    NCT02894684
    Conditions
    Cystic Fibrosis; Infection; Pseudomonas
    Interventions
    Aztreonam; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01
    Completion
    2019-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Infection; Pseudomonas
    InterventionAztreonam; Standard Care
    PhasePhase 4
    Registry statusCompleted